

# Andrew Phillips

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11582487/publications.pdf>

Version: 2024-02-01

64  
papers

9,207  
citations

87723

38  
h-index

110170

64  
g-index

64  
all docs

64  
docs citations

64  
times ranked

8415  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. <i>Journal of the International AIDS Society</i> , 2021, 24, e25690.	1.2	5
2	Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25494.	1.2	5
3	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. <i>Lancet HIV</i> , 2018, 5, e291-e300.	2.1	155
4	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 579-588.	0.9	38
5	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. <i>Lancet HIV</i> , 2018, 5, e301-e308.	2.1	34
6	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. <i>PLoS Medicine</i> , 2017, 14, e1002424.	3.9	17
7	Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. <i>Aids</i> , 2016, 30, 1629-1637.	1.0	8
8	Improvements over time in short-term mortality following myocardial infarction in HIV-positive individuals. <i>Aids</i> , 2016, 30, 1583-1596.	1.0	10
9	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	1.0	78
10	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
11	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 214-223.	0.8	180
12	HIV infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15035.	18.1	340
13	Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data. <i>Epidemiology</i> , 2015, 26, 653-660.	1.2	79
14	Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. <i>Lancet HIV</i> , 2014, 1, e32-e40.	2.1	245
15	Minimal Cognitive Impairment in UK HIV-Positive Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 120-127.	0.9	58
16	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). <i>HIV Medicine</i> , 2014, 15, 1-6.	1.0	101
17	Are antiretrovirals enough for people living with HIV?. <i>Lancet</i> , 2013, 382, 1466-1467.	6.3	3
18	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. <i>Clinical Trials</i> , 2013, 10, S5-S36.	0.7	100

#	ARTICLE	IF	CITATIONS
19	Predictors of CD4+ T-Cell Counts of HIV Type 1 "Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	1.9	7
20	Life expectancy living with HIV. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 17-25.	1.3	317
21	Persistence of HIV-1 Transmitted Drug Resistance Mutations. <i>Journal of Infectious Diseases</i> , 2013, 208, 1459-1463.	1.9	92
22	Transmission of Drug Resistant HIV and Its Potential Impact on Mortality and Treatment Outcomes in Resource-Limited Settings. <i>Journal of Infectious Diseases</i> , 2013, 207, S57-S62.	1.9	64
23	Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. <i>Aids</i> , 2013, 27, 973-979.	1.0	315
24	Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection. <i>PLoS ONE</i> , 2013, 8, e78642.	1.1	9
25	Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. <i>BMJ</i> , The, 2012, 345, e5253-e5253.	3.0	44
26	Second line protease inhibitor (PI/r) based antiretroviral therapy (ART) after non-nucleoside reverse transcriptase inhibitor (NNRTI) failure: impact of nucleoside (NRTI) backbone. <i>Antiviral Therapy</i> , 2012, 18, 213-219.	0.6	14
27	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. <i>HIV Medicine</i> , 2012, 13, 1-6.	1.0	149
28	The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. <i>Aids</i> , 2012, 26, 1691-1705.	1.0	31
29	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 294-299.	0.9	13
30	Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 363-371.	4.6	345
31	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. <i>BMJ: British Medical Journal</i> , 2011, 343, d6016-d6016.	2.4	282
32	Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. <i>Aids</i> , 2011, 25, 1497-1504.	1.0	39
33	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 253-260.	0.9	19
34	The Coding Causes of Death in HIV (CoDe) Project. <i>Epidemiology</i> , 2011, 22, 516-523.	1.2	129
35	The impact of HIV drug resistance testing on changes to treatment. <i>Aids</i> , 2011, 25, 603-610.	1.0	8
36	Predicting antiretroviral drug resistance from the latest or the cumulative genotype. <i>Antiviral Therapy</i> , 2011, 16, 373-381.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <math>\leq 200</math>, <math>\leq 350</math>, and <math>\leq 500</math> Cells/mm <sup>3</sup> : Assessment of Need Following Changes in Treatment Guidelines. <i>Clinical Infectious Diseases</i> , 2011, 53, 817-825.	2.9	180
38	HBV or HCV Coinfections and Risk of Myocardial Infarction in HIV-Infected Individuals: The D:A:D Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 1077-1086.	0.6	35
39	The Impact of Transmitted Drug-Resistance on Treatment Selection and Outcome of First-Line Highly Active Antiretroviral Therapy (HAART). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 633-639.	0.9	25
40	Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. <i>Journal of Infectious Diseases</i> , 2010, 201, 318-330.	1.9	575
41	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2010, 17, 491-501.	3.1	309
42	Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. <i>Clinical Trials</i> , 2010, 7, 19-35.	0.7	33
43	Virological Response to Initial Antiretroviral Regimens Containing Abacavir or Tenofovir. <i>Journal of Infectious Diseases</i> , 2009, 200, 710-714.	1.9	8
44	Is 1 Alanine Transaminase >200 IU Enough to Define an Alanine Transaminase Flare in HIV-Infected Populations? A New Definition Derived From a Large Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 52, 391-396.	0.9	4
45	Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. <i>Annals of Neurology</i> , 2008, 63, 213-221.	2.8	167
46	British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy 2008. <i>HIV Medicine</i> , 2008, 9, 563-608.	1.0	530
47	Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients. <i>Diabetes Care</i> , 2008, 31, 1224-1229.	4.3	448
48	Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?. <i>Aids</i> , 2007, 21, 599-606.	1.0	32
49	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. <i>New England Journal of Medicine</i> , 2007, 356, 1723-1735.	13.9	1,393
50	Temporal Trends in Postseroconversion CD4 Cell Count and HIV Load: The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. <i>Journal of Infectious Diseases</i> , 2007, 195, 525-534.	1.9	44
51	Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 517-524.	1.3	64
52	Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 38, 407-416.	0.9	46
53	Influence of Hepatitis C Virus Infection on HIV Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.	1.9	362
54	Are Specific Antiretrovirals associated with an Increased Risk of Discontinuation due to Toxicities or Patient/Physician Choice in patients with Hepatitis C Virus Coinfection?. <i>Antiviral Therapy</i> , 2005, 10, 779-790.	0.6	22

#	ARTICLE	IF	CITATIONS
55	Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. <i>Lancet, The</i> , 2001, 357, 592-598.	6.3	403
56	Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2001, 15, 1261-1268.	1.0	286
57	Will the drugs still work? Transmission of resistant HIV. <i>Nature Medicine</i> , 2001, 7, 993-994.	15.2	15
58	Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. <i>Aids</i> , 2000, 14, 2857-2867.	1.0	194
59	The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan. <i>Antiviral Therapy</i> , 2000, 5, 41-48.	0.6	263
60	HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort. <i>Antiviral Therapy</i> , 2000, 5, 49-55.	0.6	52
61	Virological response to protease inhibitor therapy in an HIV clinic cohort. <i>Aids</i> , 1999, 13, 367-373.	1.0	109
62	Dual Resistance to Zidovudine and Lamivudine in Patients Treated with Zidovudine&Lamivudine Combination Therapy: Association with Therapy Failure. <i>Journal of Infectious Diseases</i> , 1998, 177, 1521-1532.	1.9	86
63	The effects of alcohol use on rebleeding and mortality in patients with alcoholic cirrhosis following variceal haemorrhage. <i>Journal of Hepatology</i> , 1992, 14, 99-103.	1.8	28
64	Cirrhotics with variceal hemorrhage: The importance of the time interval between admission and the start of analysis for survival and rebleeding rates. <i>Hepatology</i> , 1989, 9, 801-807.	3.6	144